SINGAPORE, Aug. 26, 2025 – EUDA Health Holdings Limited (NASDAQ: EUDA) (referred to as “EUDA” or the “Company”), a prominent Singapore-based non-invasive healthcare provider active in Singapore, Malaysia, and China, announced today that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has acquired exclusive global distribution rights for a cutting-edge immune health supplement (the “Supplement”). These rights were granted by Chemokine Pte. Ltd. (“Chemokine”), a Singaporean biotechnology company specializing in molecular supplements and gene-modulating formulations.
EUDA, along with its subsidiaries, plans to market and distribute the Supplement, branded as Euda Helixé, initially within Singapore, Malaysia, and China, with future plans for expansion into additional markets. This new addition is set to strengthen EUDA’s existing wellness product range, contributing to the Company’s efforts in reshaping the regional health and wellness sector.
This Supplement features an advanced formula engineered to regulate gene expression, specifically by activating advantageous genes and deactivating detrimental ones. Utilizing state-of-the-art epigenetic technology, the Supplement aims to improve metabolism, increase vitality, support longevity, and is considered a key component in EUDA’s expanding collection of wellness products.
Drawing on previous scientific breakthroughs and established formulation methods, the Supplement offers wellness support at a molecular level. It incorporates high-quality ingredients such as:
· Deer placenta
· L-Glutathione
· Astaxanthin
· Marine collagen
· Sea-Buckthorn oil
· Grape seed oil
· New Zealand refined avocado oil
The Supplement’s capsule delivery system is designed to protect active ingredients from stomach acid, ensuring their release in areas where absorption is most effective, thereby maximizing its potency.
Core Benefits of the Supplement
1. Metabolic improvement through gene activation
2. Sustained energy and vigor, delivered by a time-release system
3. Youthfulness and skin rejuvenation driven by collagen
4. Longevity assistance via stem cell regeneration pathways
Professor Kah Meng Lim, a molecular medicine researcher with extensive scientific background, established Chemokine. Prof. Lim holds a Ph.D. in Molecular Medicine from the National University of Singapore and dedicated several years to research positions at A*STAR, Singapore’s national R&D agency. His contributions connect academic science with consumer health innovation, earning him widespread recognition for transforming intricate biological discoveries into useful health solutions.
Mr. Alfred Lim, EUDA’s CEO, stated, “Obtaining exclusive distribution rights for this unique product will strengthen our range of wellness offerings and broaden our revenue sources. The Supplement places EUDA at the vanguard of molecular precision wellness, utilizing groundbreaking gene activation technology. Thanks to our robust regional network and distribution infrastructure, we anticipate achieving sales of approximately 500,000 bottles within the coming 12 months.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) operates as a leading Singapore-based non-invasive healthcare provider throughout Asia, concentrating its efforts in Singapore, Malaysia, and China. The Company aspires to be a market leader in non-invasive and preventive healthcare, with a particular emphasis on the rapidly expanding longevity sector. Our objective is to meet the changing healthcare requirements of more than 1.8 billion individuals across the region, where over 30% of the populace is quickly aging. By providing innovative, accessible, and scientifically validated health solutions, EUDA is poised to spearhead the shift in regional healthcare from reactive medical interventions to proactive, longevity-centric care. Additionally, EUDA manages a property management business located in Singapore.
Forward-Looking Statements
This document might include forward-looking statements concerning risks and uncertainties. Such statements typically employ forward-looking terminology, including terms like “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and their variations or comparable expressions (or their negative forms). These forward-looking statements do not assure future performance, conditions, or outcomes, and encompass various known and unknown risks, uncertainties, assumptions, and other significant factors, many of which are beyond EUDA’s influence, that could lead actual results or outcomes to differ substantially from those indicated in the forward-looking statements. Readers should not place undue reliance on forward-looking statements that pertain only to the date of this document’s publication. These forward-looking statements are founded on information from EUDA and other sources deemed trustworthy by us. The Company disclaims any obligation to update or revise any forward-looking statements, whether due to new information, future occurrences, or otherwise, except as mandated by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail:
